Moleculin Biotech Inc. announced it has received a Notice of Intent to Grant for its European patent application titled "PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE." This development is expected to solidify the company's exclusivity of Annamycin, also known as naxtarubicin, in the European Union. The patent, once granted, will cover methods of making preliposomal Annamycin lyophilizate with improved stability and high purity, with a base patent term extending until 2040. This advancement is part of Moleculin's efforts to establish Annamycin as the first non-cardiotoxic anthracycline for the treatment of acute myeloid leukemia and soft tissue sarcoma lung metastases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.